.png){kind=icon}
Return
Data Challenges for Externally Controlled Trials: Viewpoint
.png){kind=icon}
OA
AI
DOI：10.2196/43484.png)
.png){kind=icon}
Original request for help.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
The preferred evidence of a large randomized controlled trial is difficult to adopt in scenarios, such as rare conditions or clinical subgroups with high unmet needs, and evidence from external sources, including real-world data, is being increasingly considered by decision makers. Real-world data originate from many sources, and identifying suitable real-world data that can be used to contextualize a single-arm trial, as an external control arm, has several challenges. In this viewpoint article, we provide an overview of the technical challenges raised by regulatory and health reimbursement agencies when evaluating comparative efficacy, such as identification, outcome, and time selection challenges. By breaking down these challenges, we provide practical solutions for researchers to consider through the approaches of detailed planning, collection, and record linkage to analyze external data for comparative efficacy.
Keywords:
external control arm
synthetic control arm
single-arm trial
real-world evidence
regulatory approval
data
clinical
decision-making
efficacy
rare conditions
trial
Journal
IF:
6
Papers:
9.7K
Citations:
5.0W
Organization
Cited Papers
The external validity of published randomized controlled trials in primary care.png)
BMC FAMILY PRACTICE
OAAI
BMC FAMILY PRACTICEIF3.2
OAAIShareSaveShareSaveShareSaveA call for an integrated approach to improve efficiency, equity and sustainability in rare disease research in the United StatesNATURE GENETICSOAAI
NATURE GENETICSIF31.8
OAAIShareSaveShareSaveShareSave
View more